Abstract
Objective: Erythrocyte deformability is a function of specially designed erythrocyte membrane properties and allows for the oxygen delivery without cell fragmentation. Impaired erythrocyte deformability in diabetes is one of the suspected factors that result in erythrocyte aggregation and the microvascular circulatory arrest. In this study, we aimed to investigate low versus high doses of sugammadex on erythrocyte deformability in streptozototocin-induced diabetic rats. Methods: Twenty-four male Wistar albino rats weighing between 225 and 300 gr were randomly divided into 4 groups. Group C (control; n =6), Group DC (diabetes control; n =6), Group DR-16S (diabetes-rocuronium-16mg sugammadex; n =6) and Group DR-96S (diabetes- rocuronium-96mg sugammadex; n =6). Rats in control and diabetes groups received a 0.9% NaCl solution at the same volume. Diabetes was induced by a single IP injection of streptozotocin (Sigma Chemical, St. Louis, MO, USA) at a dose of 55 mg.kg -1 body weight, and animals were kept alive for 30 days. At the end of the follow-up period animals’ erythrocyte deformability was measured from blood samples. Results: Serum glucose was significantly lower in Group C as compared to Groups DC, DR-16S and DR-96S ( p <0.0001). The deformability index was significantly increased in the diabetic rats ( p <0.0001). It was significantly increased in Group DR-96S as compared to Group C and DC ( p <0.0001, p =0.028, respectively). Conclusion: In this study, we showed the safety profile of low dose sugammadex in diabetic rats in terms of the erythrocyte deformability. Our findings may lead to future animal and human studies investigating sugammadex effects on erythrocyte deformability and micro/macrovascular circulation.
Highlights
Serum glucose was significantly lower in Group C as compared to Groups DC, DR-16S and DR-96S (p
We found that a high dose of sugammadex is related to the impaired erythrocyte deformability while there was no difference between erythrocyte deformability index of rats treated with a low dose of sugammadex and the non-treated group
According to our study results it can be stated that the low-dose sugammadex produces no harmful effect on erythrocyte deformability in diabetic rats
Summary
The blood glucose levels were measured 72 h after this injection. The rats were classified as diabetic if their fasting blood glucose (FBG) levels exceeded 250 mg.dl-1, and only animals with FBG levels > 250 mg.dl-1 were included in the diabetic groups. Deformability measurements were performed using erythrocyte suspensions with 5% haematocrit in a phosphate-buffered saline (PBS) buffer. The collection and the deformability measurements of the erythrocytes were performed at 22o C. Samples to be measured were prepared with 10 ml of erythrocyte suspension and PBS buffer. The calculations were performed with related computer programs by measuring the pressure changes at various times. Variations in blood glucose levels, erythrocyte deformability and rat weights between the study groups were assessed using the Kruskal–Wallis test. Statistical significance was set at a p value of
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
